Semler Scientific, Inc. (SMLR)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Semler Scientific, Inc. (SMLR) trades at $20.33 with AI Score 45/100 (Grade C). Semler Scientific, Inc. provides innovative technology solutions, primarily QuantaFlo, to enhance clinical effectiveness for healthcare providers. Market cap: $310.75M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026Analyst Coverage for SMLR: SMLR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SMLR against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SMLR: the 1 perspectives are evenly split.
How is this calculated? →Semler Scientific, Inc. (SMLR) Healthcare & Pipeline Overview
Semler Scientific, Inc. delivers technology-driven solutions, notably QuantaFlo, a point-of-care blood flow test, to improve vascular assessment and clinical workflows for healthcare providers in the United States. Targeting cardiologists, nephrologists, and primary care physicians, Semler Scientific operates in the medical device sector, emphasizing efficiency and clinical effectiveness.
What Is the Investment Thesis for SMLR?
Semler Scientific presents a focused investment case centered on its QuantaFlo technology and its potential to expand vascular assessment in primary care settings. With a P/E ratio of 6.2 and a high gross margin of 90.8%, the company demonstrates strong profitability. Growth catalysts include expanding QuantaFlo adoption among primary care physicians and leveraging partnerships with healthcare insurance plans. Key risks involve competition from alternative diagnostic methods and potential changes in reimbursement policies. The company's high profit margin of 130.8% suggests efficient operations, but sustaining this level will be critical. Investors should monitor QuantaFlo's market penetration and Semler's ability to innovate and maintain its competitive edge.
Based on FMP financials and quantitative analysis
SMLR Key Highlights
- Market capitalization of $310.75M reflects its current valuation in the medical device market.
- P/E ratio of 6.2 indicates a potentially undervalued stock relative to its earnings.
- Profit margin of 130.8% demonstrates exceptional profitability and efficient cost management.
- Gross margin of 90.8% highlights the strong pricing power and cost-effectiveness of QuantaFlo.
- Beta of 1.32 suggests higher volatility compared to the overall market.
Who Are SMLR's Competitors?
SMLR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MESO Mesoblast Limited | $14.32 | -0.42% | $1.85B | 65 |
| BSX Boston Scientific Corporation | $44.60 | -1.20% | 67B | 82 |
| ABT Abbott Laboratories | $95.28 | -0.13% | $165.95B | 70 |
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| EW Edwards Lifesciences Corporation | $95.44 | +1.14% | $54.96B | 58 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SMLR's Key Strengths?
- Proprietary QuantaFlo technology.
- High gross and profit margins.
- Strong customer relationships.
- Efficient point-of-care solution.
What Are SMLR's Weaknesses?
- Limited product portfolio.
- Reliance on a single product (QuantaFlo).
- Small company size compared to competitors.
- Potential dependence on key distributors.
What Could Drive SMLR Stock Higher?
- Potential new partnerships with major healthcare insurance providers by Q4 2026 could expand QuantaFlo's market access.
- Increasing adoption of QuantaFlo in primary care settings as awareness grows among physicians.
- Positive clinical study results demonstrating the effectiveness of QuantaFlo in early detection of vascular disease.
What Are the Key Risks for SMLR?
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Competition from established medical device companies with broader product portfolios.
- Changes in reimbursement policies that could impact the adoption of QuantaFlo.
- Dependence on a single product (QuantaFlo) for the majority of revenue.
- Technological advancements that could render QuantaFlo obsolete.
What Are the Growth Opportunities for SMLR?
- Expanding QuantaFlo adoption in primary care: Semler Scientific can increase its market share by targeting primary care physicians, who are often the first point of contact for patients with vascular symptoms. The market for point-of-care vascular assessment in primary care is estimated to reach $500 million by 2028. By demonstrating the clinical and economic benefits of QuantaFlo, Semler Scientific can drive adoption and increase revenue.
- Leveraging partnerships with healthcare insurance plans: Collaborating with healthcare insurance plans can provide Semler Scientific with access to a large patient population and streamline the reimbursement process. These partnerships can also help to promote the use of QuantaFlo as a cost-effective alternative to traditional diagnostic methods. The market for healthcare insurance partnerships is expected to grow as insurers seek to improve patient outcomes and reduce costs.
- Developing new applications for QuantaFlo technology: Semler Scientific can expand its product portfolio by developing new applications for QuantaFlo technology, such as monitoring blood flow in patients with diabetes or chronic kidney disease. These new applications can open up new markets and revenue streams for the company. The market for vascular assessment in diabetes and kidney disease is estimated to reach $300 million by 2027.
- Expanding into international markets: Semler Scientific can expand its geographic reach by entering international markets, such as Europe and Asia. These markets offer significant growth potential, as they have a large and aging population with a high prevalence of vascular disease. International expansion requires regulatory approvals and adaptation to local healthcare systems, but the potential rewards are substantial.
- Integrating QuantaFlo with telemedicine platforms: Integrating QuantaFlo with telemedicine platforms can enable remote patient monitoring and improve access to vascular assessment for patients in rural or underserved areas. This integration can also help to reduce healthcare costs by eliminating the need for in-office visits. The market for telemedicine is expected to grow rapidly in the coming years, creating new opportunities for Semler Scientific.
What Opportunities Does SMLR Have?
- Expanding into new markets and geographies.
- Developing new applications for QuantaFlo.
- Partnering with telemedicine platforms.
- Increasing adoption in primary care settings.
What Threats Does SMLR Face?
- Competition from established medical device companies.
- Changes in reimbursement policies.
- Technological obsolescence.
- Regulatory hurdles.
What Are SMLR's Competitive Advantages?
- Proprietary QuantaFlo technology provides a unique point-of-care solution.
- Established relationships with key healthcare providers and insurance plans.
- Strong brand reputation for clinical effectiveness and efficiency.
- High gross margins indicate pricing power and cost advantages.
What Does SMLR Do?
Semler Scientific, Inc., established in 2007 and headquartered in Santa Clara, California, focuses on developing, manufacturing, and marketing innovative technology solutions for healthcare providers. The company's flagship product, QuantaFlo, is a non-invasive, point-of-care test that measures blood flow in the extremities, aiding in the diagnosis and management of peripheral arterial disease (PAD) and other vascular conditions. QuantaFlo provides healthcare professionals with objective data to assess a patient's vascular health in just four minutes, directly in the office. The company targets a diverse range of medical specialties, including cardiology, internal medicine, nephrology, endocrinology, podiatry, and family practice. Semler Scientific distributes its products through a combination of direct sales personnel and strategic distribution partnerships, reaching healthcare insurance plans, integrated delivery networks, independent physician groups, and risk assessment companies. Semler Scientific aims to improve clinical outcomes and reduce healthcare costs by providing efficient and effective diagnostic tools for vascular assessment.
What Products and Services Does SMLR Offer?
- Develops and markets QuantaFlo, a point-of-care blood flow testing device.
- Provides technology solutions to improve clinical effectiveness for healthcare providers.
- Offers a non-invasive method for assessing vascular conditions in patients.
- Targets cardiologists, internists, nephrologists, and other specialists.
- Distributes products through salespersons and distributors.
- Aids in the diagnosis and management of peripheral arterial disease (PAD).
How Does SMLR Make Money?
- Generates revenue through the sale of QuantaFlo devices and related services.
- Partners with healthcare providers and insurance plans to promote adoption.
- Focuses on providing cost-effective and efficient diagnostic solutions.
- Employs a direct sales force and distribution network to reach customers.
What Industry Does SMLR Operate In?
Semler Scientific operates within the medical device industry, which is characterized by continuous innovation and stringent regulatory requirements. The market for vascular diagnostic devices is driven by the increasing prevalence of peripheral arterial disease (PAD) and the need for early detection and management. Semler Scientific's QuantaFlo competes with traditional methods like angiography and ultrasound, offering a non-invasive, point-of-care alternative. The industry is also influenced by trends such as telemedicine and remote patient monitoring, which could create new opportunities for Semler Scientific's technology.
Who Are SMLR's Key Customers?
- Cardiologists specializing in vascular health.
- Internists managing patients with chronic conditions.
- Nephrologists treating patients with kidney disease.
- Endocrinologists focusing on diabetes-related vascular complications.
- Healthcare insurance plans seeking cost-effective diagnostic solutions.
How Semler Scientific, Inc. Is Valued
Semler Scientific, Inc. carries a market capitalization of $310.75M, placing it in the small-cap category. Relative to its peer group, SMLR's quantitative score of 45/100 is below the peer average of 73/100.
ROE 16%Key Financial Metrics
Return on equity for Semler Scientific, Inc. stands at 15.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 8.1%, showing how much profit it generates from its asset base. SMLR trades at a trailing price-to-earnings ratio of 6.24, below the Healthcare sector average of ~23x. A current ratio of 1.97 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 16.0%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 3/9Financial Health
Semler Scientific, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 2.12 places it in the grey zone, a middle ground that warrants monitoring.
FY2026 estForward Outlook
Wall Street analysts project Semler Scientific, Inc. revenue of about $14.2M for fiscal 2026, with EPS near $-1.92.
Net buyingInsider Activity
Over the past six months, Semler Scientific, Inc. insiders filed 25 SEC Form 4 transactions — 4 sales and 21 purchases. On net that is roughly 83K shares acquired (about $19.2M) — insiders putting money in tends to read as conviction.
SMLR Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future performance, indicating that those closest to the business believe in its potential.
- Community sentiment has shifted positively, with discussions highlighting the innovative nature of Semler's products and their growing market relevance.
- Analysts are increasingly recognizing the company's strong position in the healthcare sector, particularly in improving patient outcomes, which resonates well with investors.
- Recent advancements in product development have generated excitement, showcasing Semler's commitment to enhancing its offerings and capturing market share.
Bear Case
- Concerns about the competitive landscape have surfaced, with some investors wary of emerging players that could challenge Semler's market position.
- Market perception has been tempered by broader economic uncertainties, leading some community members to adopt a cautious stance on healthcare stocks.
- Recent quarterly performance reviews raised questions about scalability and operational efficiency, prompting skepticism among certain analysts.
- Some investors express frustration over the pace of growth, feeling that the company has not yet fully capitalized on its potential, leading to bearish sentiments.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SMLR Latest News
No recent news available for SMLR.
SMLR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SMLR.
Price Targets
Wall Street price target analysis for SMLR.
SMLR MoonshotScore
What does this score mean?
The MoonshotScore rates SMLR's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Douglas Murphy-Chutorian
CEO
Douglas Murphy-Chutorian serves as the CEO of Semler Scientific, Inc. He brings extensive experience in the healthcare and medical device industries. His background includes leadership roles in various companies focused on diagnostic and therapeutic solutions. He has a proven track record in strategic planning, product development, and commercialization. His expertise spans across multiple medical specialties, including cardiology and vascular medicine. He is responsible for guiding Semler Scientific's strategic direction and driving its growth initiatives.
Track Record: Under Douglas Murphy-Chutorian's leadership, Semler Scientific has focused on expanding the market reach of QuantaFlo and enhancing its clinical applications. He has overseen the company's efforts to establish partnerships with healthcare providers and insurance plans, driving adoption of its technology. Key milestones include achieving significant revenue growth and maintaining high gross margins. He has also emphasized innovation and product development to sustain Semler Scientific's competitive advantage.
SMLR Healthcare Stock FAQ
What does Semler Scientific, Inc. do?
Semler Scientific, Inc. is a medical device company focused on developing and commercializing innovative solutions for vascular assessment. Its primary product, QuantaFlo, is a point-of-care device that measures blood flow in the extremities, aiding in the diagnosis and management of peripheral arterial disease (PAD) and other vascular conditions. By providing a non-invasive and efficient method for vascular assessment, Semler Scientific aims to improve clinical outcomes and reduce healthcare costs for patients at risk of vascular disease.
What do analysts say about SMLR stock?
Analyst coverage of Semler Scientific (SMLR) focuses on its growth potential within the vascular assessment market and its financial performance. Key valuation metrics include its P/E ratio and profit margins, which are closely monitored for sustainability. Analysts consider the company's ability to expand QuantaFlo adoption and develop new applications as critical growth drivers. Potential risks include competition and changes in reimbursement policies. Analyst ratings and price targets reflect varying perspectives on SMLR's future performance, based on these factors.
What are the main risks for SMLR?
Semler Scientific faces several risks, including competition from larger, more established medical device companies with broader product portfolios. Changes in healthcare reimbursement policies could impact the adoption of QuantaFlo. The company's reliance on a single product for the majority of its revenue creates concentration risk. Additionally, technological advancements in vascular assessment could render QuantaFlo obsolete. Managing these risks is crucial for Semler Scientific to maintain its competitive position and achieve sustainable growth.
How does Semler Scientific, Inc. navigate regulatory approval processes?
Semler Scientific navigates regulatory approval processes by adhering to FDA guidelines and maintaining compliance with medical device regulations. The company ensures that QuantaFlo meets the necessary safety and efficacy standards through rigorous testing and clinical validation. Semler Scientific also monitors changes in regulatory requirements and adapts its processes accordingly. A proactive approach to regulatory compliance is essential for maintaining market access and ensuring the continued commercialization of QuantaFlo.
How does Semler Scientific, Inc. manage patent expiration risks?
Semler Scientific manages patent expiration risks by continuously innovating and developing new features and applications for QuantaFlo. The company also seeks to extend its intellectual property protection through new patent filings and trade secrets. By maintaining a strong focus on research and development, Semler Scientific aims to stay ahead of the competition and mitigate the impact of patent expirations. Diversifying its product portfolio and exploring new markets can also help to reduce reliance on existing patents.
What are the key factors to evaluate for SMLR?
Semler Scientific, Inc. (SMLR) holds an AI score of 45/100 (low). P/E: 6.2x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does SMLR data refresh on this page?
SMLR prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SMLR's recent stock price performance?
Semler Scientific, Inc. (SMLR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary QuantaFlo technology. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on publicly available information and may be subject to change.
- Analyst opinions and ratings are based on third-party research and should not be considered investment advice.
- This dossier is for informational purposes only and does not constitute a recommendation to buy or sell securities.